가온NAIS AI 연구동료가칭
둘러보기 모드 — 예시 대화를 읽기 전용으로 보여 줍니다. 질문 보내기 · 다시 생성 · 파일 첨부처럼 AI 를 부르는 기능은 요금이 나가므로, 관리자가 허가한 계정으로 로그인해야 쓸 수 있습니다.

EGFR 표적 승인 약물 (UniProt · ChEMBL)

EGFR의 단백질 기능을 UniProt에서 확인하고, ChEMBL에서 EGFR을 표적으로 하는 승인 약물을 찾아 표로 정리해 줘.
K
실행 과정 26단계 · 132초
  1. 진행
    에이전트를 준비하고 있습니다.
  2. 진행
    질문에 맞는 도구와 데이터를 고르고 있습니다.
  3. 진행
    도구 17개, 데이터 5개, 라이브러리 3개를 골랐습니다.
  4. 계획
    요청은 (1) UniProt에서 인간 EGFR의 기능을 확인하고, (2) ChEMBL에서 EGFR 표적 **승인 약물**을 식별한 뒤, (3) 근거와 함께 표로 정리하는 것으로 이해했습니다. 1. [ ] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. 2. [ ] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. 3. [ ] 표적-약물 연결과 승인 상태를 검토해 표로 정리하고, 조회 한계/해석을 명시한다.1. [ ] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. 2. [ ] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. 3. [ ] 표적-약물 연결과 승인 상태를 검토해 표로 정리하고, 조회 한계/해석을 명시한다.
  5. 코드 python
    python
    from biomni.tool.database import query_uniprot
    
    egfr_uniprot = query_uniprot(
        prompt="Retrieve the reviewed human EGFR (epidermal growth factor receptor) UniProt entry, including protein function, catalytic activity, subcellular location, and accession.",
        max_results=3
    )
    print("UniProt EGFR query result:")
    print(egfr_uniprot)
  6. 실행 결과
    실행 결과 보기
    UniProt EGFR query result:
    {'success': True, 'query_info': {'endpoint': 'https://rest.uniprot.org/uniprotkb/search?query=gene_exact%3AEGFR%20AND%20organism_id%3A9606%20AND%20reviewed%3Atrue&format=json&fields=accession%2Cprotein_name%2Cgene_primary%2Corganism_name%2Ccc_function%2Ccc_catalytic_activity&size=1', 'method': 'GET', 'description': 'Retrieves the reviewed human EGFR (epidermal growth factor receptor) UniProtKB entry with its accession, protein function, catalytic activity, and protein annotations. Subcellular location is included in the full JSON entry but is not available as a specified return field in this schema.'}, 'result': {'results': [{'entryType': 'UniProtKB reviewed (Swiss-Prot)', 'primaryAccession': 'P00533', 'organism': {'scientificName': 'Homo sapiens', 'commonName': 'Human', 'taxonId': 9606, 'lineage': ['Eukaryota', 'Metazoa', 'Chordata', 'Craniata', 'Vertebrata', 'Euteleostomi', 'Mammalia', 'Eutheria', 'Euarchontoglires', 'Primates', 'Haplorrhini', 'Catarrhini', 'Hominidae', 'Homo']}, 'proteinDescription': {'recommendedName': {'fullName': {'evidences': [{'evidenceCode': 'ECO:0000305'}], 'value': 'Epidermal growth factor receptor'}, 'ecNumbers': [{'evidences': [{'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '32926474'}], 'value': '2.7.10.1'}]}, 'alternativeNames': [{'fullName': {'value': 'Proto-oncogene c-ErbB-1'}}, {'fullName': {'value': 'Receptor tyrosine-protein kinase erbB-1'}}], 'flag': 'Precursor'}, 'genes': [{'geneName': {'evidences': [{'evidenceCode': 'ECO:0000303', 'source': 'PubMed', 'id': '32926474'}, {'evidenceCode': 'ECO:0000312', 'source': 'HGNC', 'id': 'HGNC:3236'}], 'value': 'EGFR'}}], 'comments': [{'texts': [{'evidences': [{'evidenceCode': 'ECO:0000250', 'source': 'UniProtKB', 'id': 'Q01279'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '10026169'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '10805725'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '11116146'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '11483589'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '11602604'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '12297049'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '12297050'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '12620237'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '12873986'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '15374980'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '15590694'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '15611079'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '17115032'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '17349580'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '17909029'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '18046415'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '19560417'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '19836242'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '20462955'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '20837704'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '21258366'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '27153536'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '2790960'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '32926474'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '35538033'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '7679104'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '8144591'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '9419975'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '9488479'}], 'value': 'Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:10805725, PubMed:12297050, PubMed:12620237, PubMed:12873986, PubMed:15374980, PubMed:15590694, PubMed:17115032, PubMed:19560417, PubMed:21258366, PubMed:27153536, PubMed:2790960, PubMed:35538033, PubMed:9488479). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues (PubMed:10026169, PubMed:17349580, PubMed:18046415, PubMed:19560417, PubMed:19836242). The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades (PubMed:10026169, PubMed:17349580, PubMed:18046415, PubMed:19560417, PubMed:19836242). Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Acts as a positive regulator of cGAS-STING signaling by mediating tyrosine phosphorylation of STING1, promoting production of type I interferon (IFN-alpha and IFN-beta), while inhibiting STING1 ability to regulate autophagy (PubMed:32926474). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity)'}], 'commentType': 'FUNCTION'}, {'texts': [{'evidences': [{'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '8918811'}], 'value': 'May act as an antagonist of EGF action'}], 'commentType': 'FUNCTION', 'molecule': 'Isoform 2'}, {'texts': [{'evidences': [{'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '21516087'}], 'value': '(Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins'}], 'commentType': 'FUNCTION'}, {'commentType': 'CATALYTIC ACTIVITY', 'reaction': {'name': 'L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+)', 'reactionCrossReferences': [{'database': 'Rhea', 'id': 'RHEA:10596'}, {'database': 'Rhea', 'id': 'RHEA-COMP:10136'}, {'database': 'Rhea', 'id': 'RHEA-COMP:20101'}, {'database': 'ChEBI', 'id': 'CHEBI:15378'}, {'database': 'ChEBI', 'id': 'CHEBI:30616'}, {'database': 'ChEBI', 'id': 'CHEBI:46858'}, {'database': 'ChEBI', 'id': 'CHEBI:61978'}, {'database': 'ChEBI', 'id': 'CHEBI:456216'}], 'ecNumber': '2.7.10.1', 'evidences': [{'evidenceCode': 'ECO:0000255', 'source': 'PROSITE-ProRule', 'id': 'PRU10028'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '15374980'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '17349580'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '18046415'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '18227510'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '19560417'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '19563760'}, {'evidenceCode': 'ECO:0000269', 'source': 'PubMed', 'id': '32926474'}]}}], 'extraAttributes': {'uniParcId': 'UPI000003E750'}}]}}
  7. 계획
    UniProt 조회로 인간 EGFR의 검토 완료(Swiss-Prot) 항목 **P00533** 및 기능·촉매활성 주석을 확인했습니다. 1. [✓] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. (P00533; 리간드 의존적 수용체 티로신 키나아제이며, 이합체화/자가인산화 후 RAS–RAF–MEK–ERK, PI3K–AKT, PLCγ–PKC, STAT 등의 경로를 활성화함) 2. [ ] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. 3. [ ] 표적-약물 연결과 승인 상태를 검토해 표로 정리하고, 조회 한계/해석을 명시한다.
  8. 코드 python
    python
    from biomni.tool.database import query_chembl
    
    chembl_egfr = query_chembl(
        prompt=(
            "Find the human epidermal growth factor receptor EGFR target in ChEMBL, "
            "and retrieve approved drugs (maximum phase 4) with direct EGFR target activity. "
            "Include ChEMBL target ID, molecule ChEMBL ID, preferred name, maximum phase, "
            "molecule type, and mechanism of action where available."
        ),
        max_results=100,
        verbose=True
    )
    print("ChEMBL EGFR approved-drug query result:")
    print(chembl_egfr)
  9. 실행 결과
    실행 결과 보기
    The output is too long to be added to context. Here are the first 10K characters...
    ChEMBL EGFR approved-drug query result:
    {'success': True, 'query_info': {'endpoint': 'https://www.ebi.ac.uk/chembl/api/data/molecule/search.json?q=human&limit=100', 'method': 'GET', 'description': 'Search for molecule human in ChEMBL database'}, 'result': {'molecules': [{'atc_classifications': ['B05AA01'], 'availability_type': 1, 'biotherapeutic': {'biocomponents': [], 'description': 'Serum albumin precursor', 'helm_notation': None, 'molecule_chembl_id': 'CHEMBL1201451'}, 'black_box_warning': 0, 'chemical_probe': 0, 'chirality': 1, 'cross_references': [], 'dosed_ingredient': True, 'first_approval': 1997, 'first_in_class': 0, 'helm_notation': None, 'inorganic_flag': 0, 'max_phase': '4.0', 'molecule_chembl_id': 'CHEMBL1201451', 'molecule_hierarchy': {'active_chembl_id': 'CHEMBL1201451', 'molecule_chembl_id': 'CHEMBL1201451', 'parent_chembl_id': 'CHEMBL1201451'}, 'molecule_properties': None, 'molecule_structures': None, 'molecule_synonyms': [{'molecule_synonym': 'Albumin', 'syn_type': 'ATC', 'synonyms': 'ALBUMIN'}, {'molecule_synonym': 'Albuminar-5', 'syn_type': 'TRADE_NAME', 'synonyms': 'ALBUMINAR-5'}, {'molecule_synonym': 'Albumin, blood', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN, BLOOD'}, {'molecule_synonym': 'Albumin (bovine)', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN (BOVINE)'}, {'molecule_synonym': 'Albumin bovine', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN BOVINE'}, {'molecule_synonym': 'Albumin, bovine', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN, BOVINE'}, {'molecule_synonym': 'Albumin (human)', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN (HUMAN)'}, {'molecule_synonym': 'Albumin human', 'syn_type': 'FDA', 'synonyms': 'ALBUMIN HUMAN'}, {'molecule_synonym': 'Albumin human', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN HUMAN'}, {'molecule_synonym': 'Albumin, human', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN, HUMAN'}, {'molecule_synonym': 'Albumin,human', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN,HUMAN'}, {'molecule_synonym': 'Albumin human component of abi-009', 'syn_type': 'TRADE_NAME', 'synonyms': 'ALBUMIN HUMAN COMPONENT OF ABI-009'}, {'molecule_synonym': 'Albumin human. plasma-derived', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN HUMAN. PLASMA-DERIVED'}, {'molecule_synonym': 'Albumin microspheres, human', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN MICROSPHERES, HUMAN'}, {'molecule_synonym': 'Albumin. plasma-derived', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN. PLASMA-DERIVED'}, {'molecule_synonym': 'Albumin test', 'syn_type': 'OTHER', 'synonyms': 'ALBUMIN TEST'}, {'molecule_synonym': 'Albumisol', 'syn_type': 'OTHER', 'synonyms': 'ALBUMISOL'}, {'molecule_synonym': 'Albutein', 'syn_type': 'OTHER', 'synonyms': 'ALBUTEIN'}, {'molecule_synonym': 'Allergen: bos d 6', 'syn_type': 'OTHER', 'synonyms': 'ALLERGEN: BOS D 6'}, {'molecule_synonym': 'Bovine albumin', 'syn_type': 'OTHER', 'synonyms': 'BOVINE ALBUMIN'}, {'molecule_synonym': 'Bovine serum albumin', 'syn_type': 'OTHER', 'synonyms': 'BOVINE SERUM ALBUMIN'}, {'molecule_synonym': 'Bsa for protein quantitation', 'syn_type': 'OTHER', 'synonyms': 'BSA FOR PROTEIN QUANTITATION'}, {'molecule_synonym': 'Buminate', 'syn_type': 'TRADE_NAME', 'synonyms': 'BUMINATE'}, {'molecule_synonym': 'Fraction v', 'syn_type': 'OTHER', 'synonyms': 'FRACTION V'}, {'molecule_synonym': 'Human albumin', 'syn_type': 'OTHER', 'synonyms': 'HUMAN ALBUMIN'}, {'molecule_synonym': 'Human serum albumin', 'syn_type': 'OTHER', 'synonyms': 'HUMAN SERUM ALBUMIN'}, {'molecule_synonym': 'Normal human serum albumin', 'syn_type': 'OTHER', 'synonyms': 'NORMAL HUMAN SERUM ALBUMIN'}, {'molecule_synonym': 'Plasbumin', 'syn_type': 'TRADE_NAME', 'synonyms': 'PLASBUMIN'}, {'molecule_synonym': 'Serum albumin', 'syn_type': 'OTHER', 'synonyms': 'SERUM ALBUMIN'}, {'molecule_synonym': 'Serum albumin bovine', 'syn_type': 'OTHER', 'synonyms': 'SERUM ALBUMIN BOVINE'}], 'molecule_type': 'Protein', 'natural_product': 0, 'oral': False, 'orphan': 0, 'parenteral': True, 'polymer_flag': 0, 'pref_name': 'ALBUMIN HUMAN', 'prodrug': 0, 'score': 29.0, 'structure_type': 'SEQ', 'therapeutic_flag': True, 'topical': False, 'usan_stem': None, 'usan_stem_definition': None, 'usan_substem': None, 'usan_year': None, 'veterinary': 0, 'withdrawn_flag': False}, {'atc_classifications': ['B01AD05'], 'availability_type': 0, 'biotherapeutic': None, 'black_box_warning': 0, 'chemical_probe': 0, 'chirality': 1, 'cross_references': [], 'dosed_ingredient': True, 'first_approval': 1964, 'first_in_class': 0, 'helm_notation': None, 'inorganic_flag': 0, 'max_phase': '4.0', 'molecule_chembl_id': 'CHEMBL1201505', 'molecule_hierarchy': {'active_chembl_id': 'CHEMBL1201505', 'molecule_chembl_id': 'CHEMBL1201505', 'parent_chembl_id': 'CHEMBL1201505'}, 'molecule_properties': None, 'molecule_structures': None, 'molecule_synonyms': [{'molecule_synonym': 'Fibrinolisina (humana)', 'syn_type': 'INN_SPANISH', 'synonyms': 'FIBRINOLISINA (HUMANA)'}, {'molecule_synonym': 'Fibrinolysin', 'syn_type': 'ATC', 'synonyms': 'FIBRINOLYSIN'}, {'molecule_synonym': 'Fibrinolysin', 'syn_type': 'OTHER', 'synonyms': 'FIBRINOLYSIN'}, {'molecule_synonym': 'Fibrinolysine (humaine)', 'syn_type': 'INN_FRENCH', 'synonyms': 'FIBRINOLYSINE (HUMAINE)'}, {'molecule_synonym': 'Fibrinolysin (human)', 'syn_type': 'INN', 'synonyms': 'FIBRINOLYSIN (HUMAN)'}, {'molecule_synonym': 'Fibrinolysin human', 'syn_type': 'OTHER', 'synonyms': 'FIBRINOLYSIN HUMAN'}, {'molecule_synonym': 'Fibrinolysin, human', 'syn_type': 'OTHER', 'synonyms': 'FIBRINOLYSIN, HUMAN'}, {'molecule_synonym': 'Plasmin', 'syn_type': 'MERCK_INDEX', 'synonyms': 'PLASMIN'}, {'molecule_synonym': 'Plasmin (bos taurus)', 'syn_type': 'OTHER', 'synonyms': 'PLASMIN (BOS TAURUS)'}, {'molecule_synonym': 'Plasmin (bovine)', 'syn_type': 'OTHER', 'synonyms': 'PLASMIN (BOVINE)'}, {'molecule_synonym': 'Plasmin bovine', 'syn_type': 'OTHER', 'synonyms': 'PLASMIN BOVINE'}, {'molecule_synonym': 'Plasmin (human)', 'syn_type': 'OTHER', 'synonyms': 'PLASMIN (HUMAN)'}, {'molecule_synonym': 'Thrombolysin.', 'syn_type': 'OTHER', 'synonyms': 'THROMBOLYSIN.'}], 'molecule_type': 'Unknown', 'natural_product': 0, 'oral': False, 'orphan': 0, 'parenteral': False, 'polymer_flag': 0, 'pref_name': 'FIBRINOLYSIN, HUMAN', 'prodrug': 0, 'score': 29.0, 'structure_type': 'NONE', 'therapeutic_flag': True, 'topical': True, 'usan_stem': None, 'usan_stem_definition': None, 'usan_substem': None, 'usan_year': None, 'veterinary': 0, 'withdrawn_flag': False}, {'atc_classifications': ['A10AF01', 'A10AC01', 'A10AD01', 'A10AB01', 'A10AE01'], 'availability_type': 2, 'biotherapeutic': {'biocomponents': [{'component_id': 29816, 'component_type': 'Protein', 'description': 'Heavy chain', 'organism': None, 'sequence': 'FVNQHLCGSHLVEALYLVCGERGFFYTPKT', 'tax_id': None}, {'component_id': 29818, 'component_type': 'Protein', 'description': 'Light chain', 'organism': None, 'sequence': 'GIVEQCCTSICSLYQLENYCN', 'tax_id': None}], 'description': 'Recombinant human insulin', 'helm_notation': None, 'molecule_chembl_id': 'CHEMBL1201631'}, 'black_box_warning': 1, 'chemical_probe': 0, 'chirality': 1, 'cross_references': [{'xref_id': 'insulin%20human', 'xref_name': 'insulin human', 'xref_src': 'DailyMed'}, {'xref_id': 'insulin%20recombinant%20human', 'xref_name': 'insulin recombinant human', 'xref_src': 'DailyMed'}, {'xref_id': 'human/EPAR/actrapid', 'xref_name': 'actrapid', 'xref_src': 'EMA'}, {'xref_id': 'human/EPAR/exubera', 'xref_name': 'exubera', 'xref_src': 'EMA'}, {'xref_id': 'human/EPAR/inpremzia', 'xref_name': 'inpremzia', 'xref_src': 'EMA'}, {'xref_id': 'human/EPAR/insuman', 'xref_name': 'insuman', 'xref_src': 'EMA'}, {'xref_id': 'human/EPAR/velosulin', 'xref_name': 'velosulin', 'xref_src': 'EMA'}], 'dosed_ingredient': True, 'first_approval': 1982, 'first_in_class': 0, 'helm_notation': None, 'inorganic_flag': 0, 'max_phase': '4.0', 'molecule_chembl_id': 'CHEMBL1201631', 'molecule_hierarchy': {'active_chembl_id': 'CHEMBL1201631', 'molecule_chembl_id': 'CHEMBL1201631', 'parent_chembl_id': 'CHEMBL1201631'}, 'molecule_properties': None, 'molecule_structures': None, 'molecule_synonyms': [{'molecule_synonym': 'Actrapid', 'syn_type': 'TRADE_NAME', 'synonyms': 'ACTRAPID'}, {'molecule_synonym': 'Afrezza', 'syn_type': 'TRADE_NAME', 'synonyms': 'AFREZZA'}, {'molecule_synonym': 'Biosulin r', 'syn_type': 'OTHER', 'synonyms': 'BIOSULIN R'}, {'molecule_synonym': 'Capsulin', 'syn_type': 'OTHER', 'synonyms': 'CAPSULIN'}, {'molecule_synonym': 'Exubera', 'syn_type': 'TRADE_NAME', 'synonyms': 'EXUBERA'}, {'molecule_synonym': 'Exubera (inhaled insulin human)', 'syn_type': 'OTHER', 'synonyms': 'EXUBERA (INHALED INSULIN HUMAN)'}, {'molecule_synonym': 'High molecular weight insulin human', 'syn_type': 'USP', 'synonyms': 'HIGH MOLECULAR WEIGHT INSULIN HUMAN'}, {'molecule_synonym': 'Human insulin', 'syn_type': 'OTHER', 'synonyms': 'HUMAN INSULIN'}, {'molecule_synonym': 'Humulin', 'syn_type': 'OTHER', 'synonyms': 'HUMULIN'}, {'molecule_synonym': 'Humulin br', 'syn_type': 'TRADE_NAME', 'synonyms': 'HUMULIN BR'}, {'molecule_synonym': 'Humulin r', 'syn_type': 'TRADE_NAME', 'synonyms': 'HUMULIN R'}, {'molecule_synonym': 'Inpremzia', 'syn_type': 'TRADE_NAME', 'synonyms': 'INPREMZIA'}, {'molecule_synonym': 'Ins humulin r', 'syn_type': 'TRADE_NAME', 'synonyms': 'INS HUMULIN R'}, {'molecule_synonym': 'Insulin', 'syn_type': 'OTHER', 'synonyms': 'INSULIN'}, {'molecule_synonym': 'Insulina humana', 'syn_type': 'INN_SPANISH', 'synonyms': 'INSULINA HUMANA'}, {'molecule_synonym': 'Insuline humaine', 'syn_type': 'INN_FRENCH', 'synonyms': 'INSULINE HUMAINE'}, {'molecule_synonym': 'Insulin (human)', 'syn_type': 'ATC', 'synonyms': 'INSULIN (HUMAN)'}, {'molecule_synonym': 'Insulin human', 'syn_type': 'BAN', 'synonyms': 'INSULIN HUMAN'}, {'molecule_synonym': 'Insulin human', 'syn_type': 'BNF', 'synonyms': 'INSULIN HUMAN'}, {'molecule_synonym': 'Insulin human', 'syn_type': 'EMA', 'synonyms': 'INSULIN HUMAN'}, {'molecule_synonym': 'Insulin human', 'syn_type': 'INN', 'synonyms': 'INSULIN HUMAN'}, {'molecule_synonym': 'Insulin human', 'syn_type': '
  10. 계획
    앞선 자연어 ChEMBL 검색은 EGFR 표적을 직접 필터링하지 못하고 “human”이라는 분자명 검색으로 해석되어, 목적과 무관한 결과를 반환했습니다. 따라서 ChEMBL의 **기전(mechanism) 데이터에서 표적 ID `CHEMBL203`(EGFR)를 직접 지정**하고, 승인 상태는 분자 메타데이터의 `max_phase = 4`로 교차 확인하겠습니다. 1. [✓] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. (P00533 확인) 2. [ ] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. (직전 검색이 표적 필터 없이 수행되어 직접 API 필터 방식으로 수정) 3. [ ] 표적-약물 연결과 승인 상태를 검토해 표로 정리하고, 조회 한계/해석을 명시한다.
  11. 코드 python
    python
    from biomni.tool.database import query_chembl
    
    mechanisms = query_chembl(
        prompt="Retrieve ChEMBL mechanisms of action for EGFR target CHEMBL203.",
        endpoint="https://www.ebi.ac.uk/chembl/api/data/mechanism.json?target_chembl_id=CHEMBL203&limit=100",
        max_results=100,
        verbose=True
    )
    print("Direct ChEMBL EGFR mechanism query:")
    print(mechanisms)
  12. 실행 결과
    실행 결과 보기
    The output is too long to be added to context. Here are the first 10K characters...
    Direct ChEMBL EGFR mechanism query:
    {'success': True, 'query_info': {'endpoint': 'https://www.ebi.ac.uk/chembl/api/data/target.json?limit=100', 'method': 'GET', 'description': 'Search for target data in ChEMBL database'}, 'result': {'page_meta': {'limit': 100, 'next': '/chembl/api/data/target.json?limit=100&offset=100', 'offset': 0, 'previous': None, 'total_count': 18552}, 'targets': [{'cross_references': [], 'organism': 'Homo sapiens', 'pref_name': 'Maltase-glucoamylase', 'species_group_flag': False, 'target_chembl_id': 'CHEMBL2074', 'target_components': [{'accession': 'O43451', 'component_description': 'Maltase-glucoamylase', 'component_id': 434, 'component_type': 'PROTEIN', 'relationship': 'SINGLE PROTEIN', 'target_component_synonyms': [{'component_synonym': '3.2.1.20', 'syn_type': 'EC_NUMBER'}, {'component_synonym': 'Alpha-1,4-glucosidase', 'syn_type': 'UNIPROT'}, {'component_synonym': 'Maltase-glucoamylase', 'syn_type': 'UNIPROT'}, {'component_synonym': 'MGA', 'syn_type': 'GENE_SYMBOL_OTHER'}, {'component_synonym': 'MGAM', 'syn_type': 'GENE_SYMBOL'}, {'component_synonym': 'MGAML', 'syn_type': 'GENE_SYMBOL_OTHER'}, {'component_synonym': 'Synonyms=MGA', 'syn_type': 'GENE_SYMBOL_OTHER'}], 'target_component_xrefs': [{'xref_id': 'O43451', 'xref_name': None, 'xref_src_db': 'AlphaFoldDB'}, {'xref_id': 'O43451', 'xref_name': None, 'xref_src_db': 'ExpressionAtlas'}, {'xref_id': 'GO:0005886', 'xref_name': 'plasma membrane', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0016324', 'xref_name': 'apical plasma membrane', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0070062', 'xref_name': 'extracellular exosome', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0070821', 'xref_name': 'tertiary granule membrane', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0101003', 'xref_name': 'ficolin-1-rich granule membrane', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0003824', 'xref_name': 'catalytic activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0004339', 'xref_name': 'glucan 1,4-alpha-glucosidase activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0004553', 'xref_name': 'hydrolase activity, hydrolyzing O-glycosyl compounds', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0004558', 'xref_name': 'alpha-1,4-glucosidase activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0004574', 'xref_name': 'oligo-1,6-glucosidase activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0005515', 'xref_name': 'protein binding', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0016160', 'xref_name': 'amylase activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0016798', 'xref_name': 'hydrolase activity, acting on glycosyl bonds', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0030246', 'xref_name': 'carbohydrate binding', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0090599', 'xref_name': 'alpha-glucosidase activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0000025', 'xref_name': 'maltose catabolic process', 'xref_src_db': 'GoProcess'}, {'xref_id': 'GO:0005975', 'xref_name': 'carbohydrate metabolic process', 'xref_src_db': 'GoProcess'}, {'xref_id': 'GO:0005983', 'xref_name': 'starch catabolic process', 'xref_src_db': 'GoProcess'}, {'xref_id': 'GO:1901027', 'xref_name': 'dextrin catabolic process', 'xref_src_db': 'GoProcess'}, {'xref_id': 'HGNC:7043', 'xref_name': 'MGAM', 'xref_src_db': 'HGNC'}, {'xref_id': 'O43451', 'xref_name': None, 'xref_src_db': 'IntAct'}, {'xref_id': 'IPR000322', 'xref_name': 'Glyco_hydro_31_TIM', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR000519', 'xref_name': 'P_trefoil_dom', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR011013', 'xref_name': 'Gal_mutarotase_sf_dom', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR013780', 'xref_name': 'Glyco_hydro_b', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR017853', 'xref_name': 'GH', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR017957', 'xref_name': 'P_trefoil_CS', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR025887', 'xref_name': 'Glyco_hydro_31_N_dom', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR030458', 'xref_name': 'Glyco_hydro_31_AS', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR030459', 'xref_name': 'Glyco_hydro_31_CS', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR044913', 'xref_name': 'P_trefoil_dom_sf', 'xref_src_db': 'InterPro'}, {'xref_id': 'IPR048395', 'xref_name': 'Glyco_hydro_31_C', 'xref_src_db': 'InterPro'}, {'xref_id': 'PTHR22762', 'xref_name': 'ALPHA-GLUCOSIDASE', 'xref_src_db': 'PANTHER'}, {'xref_id': 'PTHR22762:SF63', 'xref_name': 'MALTASE-GLUCOAMYLASE', 'xref_src_db': 'PANTHER'}, {'xref_id': '2QLY', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '2QMJ', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3CTT', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3L4T', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3L4U', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3L4V', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3L4W', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3L4X', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3L4Y', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3L4Z', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3TON', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '3TOP', 'xref_name': None, 'xref_src_db': 'PDB'}, {'xref_id': '2QLY', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '2QMJ', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3CTT', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3L4T', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3L4U', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3L4V', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3L4W', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3L4X', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3L4Y', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3L4Z', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3TON', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': '3TOP', 'xref_name': 'A', 'xref_src_db': 'PDBe'}, {'xref_id': 'PF00088', 'xref_name': 'Trefoil', 'xref_src_db': 'Pfam'}, {'xref_id': 'PF01055', 'xref_name': 'Glyco_hydro_31_2nd', 'xref_src_db': 'Pfam'}, {'xref_id': 'PF13802', 'xref_name': 'Gal_mutarotas_2', 'xref_src_db': 'Pfam'}, {'xref_id': 'PF21365', 'xref_name': 'Glyco_hydro_31_3rd', 'xref_src_db': 'Pfam'}, {'xref_id': 'PA30778', 'xref_name': 'maltase-glucoamylase', 'xref_src_db': 'PharmGKB'}, {'xref_id': 'O43451', 'xref_name': None, 'xref_src_db': 'Pharos'}, {'xref_id': 'R-HSA-189085', 'xref_name': 'Digestion of dietary carbohydrate', 'xref_src_db': 'Reactome'}, {'xref_id': 'R-HSA-6798695', 'xref_name': 'Neutrophil degranulation', 'xref_src_db': 'Reactome'}, {'xref_id': 'E7ER45', 'xref_name': 'Maltase-glucoamylase', 'xref_src_db': 'UniProt'}, {'xref_id': 'O43451', 'xref_name': 'Maltase-glucoamylase', 'xref_src_db': 'UniProt'}, {'xref_id': 'Q0VAX6', 'xref_name': 'Maltase-glucoamylase', 'xref_src_db': 'UniProt'}, {'xref_id': 'Q75ME7', 'xref_name': 'Maltase-glucoamylase', 'xref_src_db': 'UniProt'}, {'xref_id': 'Q86UM5', 'xref_name': 'Maltase-glucoamylase', 'xref_src_db': 'UniProt'}]}], 'target_type': 'SINGLE PROTEIN', 'tax_id': 9606}, {'cross_references': [], 'organism': 'Homo sapiens', 'pref_name': 'ATP-binding cassette sub-family C member 9', 'species_group_flag': False, 'target_chembl_id': 'CHEMBL1971', 'target_components': [{'accession': 'O60706', 'component_description': 'ATP-binding cassette sub-family C member 9', 'component_id': 294, 'component_type': 'PROTEIN', 'relationship': 'SINGLE PROTEIN', 'target_component_synonyms': [{'component_synonym': 'ABCC9', 'syn_type': 'GENE_SYMBOL'}, {'component_synonym': 'ATP-binding cassette sub-family C member 9', 'syn_type': 'UNIPROT'}, {'component_synonym': 'Sulfonylurea receptor 2', 'syn_type': 'UNIPROT'}, {'component_synonym': 'SUR2', 'syn_type': 'GENE_SYMBOL_OTHER'}], 'target_component_xrefs': [{'xref_id': 'O60706', 'xref_name': None, 'xref_src_db': 'AlphaFoldDB'}, {'xref_id': 'O60706', 'xref_name': None, 'xref_src_db': 'ExpressionAtlas'}, {'xref_id': 'GO:0005737', 'xref_name': 'cytoplasm', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0005739', 'xref_name': 'mitochondrion', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0005886', 'xref_name': 'plasma membrane', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0008282', 'xref_name': 'inward rectifying potassium channel', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0016020', 'xref_name': 'membrane', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0030017', 'xref_name': 'sarcomere', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0031004', 'xref_name': 'potassium ion-transporting ATPase complex', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0032991', 'xref_name': 'protein-containing complex', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0042383', 'xref_name': 'sarcolemma', 'xref_src_db': 'GoComponent'}, {'xref_id': 'GO:0005267', 'xref_name': 'potassium channel activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0005524', 'xref_name': 'ATP binding', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0008281', 'xref_name': 'sulfonylurea receptor activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0015272', 'xref_name': 'ATP-activated inward rectifier potassium channel activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0016887', 'xref_name': 'ATP hydrolysis activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0019829', 'xref_name': 'ATPase-coupled monoatomic cation transmembrane transporter activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0042626', 'xref_name': 'ATPase-coupled transmembrane transporter activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0043225', 'xref_name': 'ATPase-coupled inorganic anion transmembrane transporter activity', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0044325', 'xref_name': 'transmembrane transporter binding', 'xref_src_db': 'GoFunction'}, {'xref_id': 'GO:0140359', 'xref_name': 'ABC-type transporter activity', 'xref_src_db': 'GoFunction'}, {'x
  13. 계획
    직접 endpoint를 전달했지만 도구의 내부 라우팅이 이를 무시하여 전체 표적 목록을 반환했습니다. 이제 ChEMBL REST API를 직접 호출해 `CHEMBL203`으로 필터링된 기전 레코드를 가져오고, 각 분자의 승인 단계와 명칭을 확인하겠습니다. 1. [✓] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. (P00533 확인) 2. [ ] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. (도구 라우팅 오류로 ChEMBL REST API 직접 조회로 변경) 3. [ ] 표적-약물 연결과 승인 상태를 검토해 표로 정리하고, 조회 한계/해석을 명시한다.
  14. 코드 python
    python
    import requests, json, pandas as pd
    from pathlib import Path
    
    base = "https://www.ebi.ac.uk/chembl/api/data"
    target_url = f"{base}/target/CHEMBL203.json"
    mech_url = f"{base}/mechanism.json"
    
    target_response = requests.get(target_url, timeout=30)
    target_response.raise_for_status()
    target = target_response.json()
    
    all_mechanisms = []
    offset = 0
    while True:
        r = requests.get(
            mech_url,
            params={"target_chembl_id": "CHEMBL203", "limit": 100, "offset": offset},
            timeout=30,
        )
        r.raise_for_status()
        payload = r.json()
        rows = payload.get("mechanisms", [])
        all_mechanisms.extend(rows)
        if not payload.get("page_meta", {}).get("next"):
            break
        offset += 100
    
    print("Target:", target.get("target_chembl_id"), "|", target.get("pref_name"), "|", target.get("organism"))
    print("EGFR-filtered mechanism records:", len(all_mechanisms))
    print("Unique molecule IDs:", len({x.get('molecule_chembl_id') for x in all_mechanisms}))
    print("First 5 mechanism records:")
    for x in all_mechanisms[:5]:
        print({k: x.get(k) for k in ["molecule_chembl_id", "mechanism_of_action", "action_type", "target_chembl_id"]})
    
    Path("egfr_chembl_mechanisms.json").write_text(
        json.dumps(all_mechanisms, ensure_ascii=False, indent=2), encoding="utf-8"
    )
    print("Saved raw filtered mechanisms: egfr_chembl_mechanisms.json")
  15. 실행 결과
    실행 결과 보기
    Target: CHEMBL203 | Epidermal growth factor receptor | Homo sapiens
    EGFR-filtered mechanism records: 90
    Unique molecule IDs: 76
    First 5 mechanism records:
    {'molecule_chembl_id': 'CHEMBL1201827', 'mechanism_of_action': 'Epidermal growth factor receptor erbB1 inhibitor', 'action_type': 'INHIBITOR', 'target_chembl_id': 'CHEMBL203'}
    {'molecule_chembl_id': 'CHEMBL1201577', 'mechanism_of_action': 'Epidermal growth factor receptor erbB1 inhibitor', 'action_type': 'INHIBITOR', 'target_chembl_id': 'CHEMBL203'}
    {'molecule_chembl_id': 'CHEMBL1079742', 'mechanism_of_action': 'Epidermal growth factor receptor erbB1 inhibitor', 'action_type': 'INHIBITOR', 'target_chembl_id': 'CHEMBL203'}
    {'molecule_chembl_id': 'CHEMBL939', 'mechanism_of_action': 'Epidermal growth factor receptor erbB1 inhibitor', 'action_type': 'INHIBITOR', 'target_chembl_id': 'CHEMBL203'}
    {'molecule_chembl_id': 'CHEMBL1201179', 'mechanism_of_action': 'Epidermal growth factor receptor erbB1 inhibitor', 'action_type': 'INHIBITOR', 'target_chembl_id': 'CHEMBL203'}
    Saved raw filtered mechanisms: egfr_chembl_mechanisms.json
  16. 파일
    egfr_chembl_mechanisms.json
  17. 계획
    ChEMBL REST API에서 인간 EGFR 표적(**CHEMBL203**)을 확인했고, EGFR에 연결된 기전 레코드 90건(고유 분자 76개)을 확보했습니다. 다음으로 각 분자의 ChEMBL 메타데이터를 조회하여 `max_phase = 4`인 승인 약물만 추출하고, 기전 정보를 결합하겠습니다. 1. [✓] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. (P00533 확인) 2. [ ] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. (EGFR/CHEMBL203 기전 레코드 90건 확보; 승인 단계 필터링 진행) 3. [ ] 표적-약물 연결과 승인 상태를 검토해 표로 정리하고, 조회 한계/해석을 명시한다.
  18. 코드 python
    python
    import json, time, requests, pandas as pd
    from pathlib import Path
    
    mechanisms = json.loads(Path("egfr_chembl_mechanisms.json").read_text(encoding="utf-8"))
    molecule_ids = sorted({m["molecule_chembl_id"] for m in mechanisms if m.get("molecule_chembl_id")})
    
    molecule_rows = []
    for i, chembl_id in enumerate(molecule_ids, 1):
        response = requests.get(
            f"https://www.ebi.ac.uk/chembl/api/data/molecule/{chembl_id}.json",
            timeout=30
        )
        response.raise_for_status()
        mol = response.json()
        molecule_rows.append({
            "molecule_chembl_id": chembl_id,
            "pref_name": mol.get("pref_name"),
            "max_phase": mol.get("max_phase"),
            "first_approval": mol.get("first_approval"),
            "molecule_type": mol.get("molecule_type"),
            "withdrawn_flag": mol.get("withdrawn_flag"),
            "atc_classifications": "; ".join(mol.get("atc_classifications") or []),
        })
        if i % 20 == 0 or i == len(molecule_ids):
            print(f"Retrieved {i}/{len(molecule_ids)} ChEMBL molecule records")
        time.sleep(0.08)
    
    mol_df = pd.DataFrame(molecule_rows)
    mech_df = pd.DataFrame([{
        "molecule_chembl_id": x.get("molecule_chembl_id"),
        "mechanism_of_action": x.get("mechanism_of_action"),
        "action_type": x.get("action_type"),
        "target_chembl_id": x.get("target_chembl_id"),
    } for x in mechanisms])
    
    approved = (
        mech_df.merge(mol_df, on="molecule_chembl_id", how="left")
        .loc[lambda d: pd.to_numeric(d["max_phase"], errors="coerce").eq(4)]
        .drop_duplicates()
        .sort_values(["pref_name", "mechanism_of_action"])
    )
    approved.to_csv("chembl_egfr_approved_drugs_raw.csv", index=False, encoding="utf-8-sig")
    mol_df.to_csv("chembl_egfr_all_molecule_metadata.csv", index=False, encoding="utf-8-sig")
    
    print("\nApproved EGFR-linked ChEMBL rows:", len(approved))
    print("Unique approved molecules:", approved["molecule_chembl_id"].nunique())
    print(approved[["pref_name", "molecule_chembl_id", "first_approval", "molecule_type",
                    "withdrawn_flag", "mechanism_of_action", "action_type"]].to_string(index=False))
    print("\nSaved: chembl_egfr_approved_drugs_raw.csv and chembl_egfr_all_molecule_metadata.csv")
  19. 실행 결과
    실행 결과 보기
    Retrieved 20/76 ChEMBL molecule records
    Retrieved 40/76 ChEMBL molecule records
    Retrieved 60/76 ChEMBL molecule records
    Retrieved 76/76 ChEMBL molecule records
    
    Approved EGFR-linked ChEMBL rows: 20
    Unique approved molecules: 20
                  pref_name molecule_chembl_id  first_approval  molecule_type  withdrawn_flag                              mechanism_of_action action_type
         AFATINIB DIMALEATE      CHEMBL2105712          2013.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                AMIVANTAMAB      CHEMBL4297774          2021.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                 BRIGATINIB      CHEMBL3545311          2017.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                  CETUXIMAB      CHEMBL1201577          2004.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                DACOMITINIB      CHEMBL2105719          2018.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
      DACOMITINIB ANHYDROUS      CHEMBL2110732          2018.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
    ERLOTINIB HYDROCHLORIDE      CHEMBL1079742          2004.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                  GEFITINIB          CHEMBL939          2003.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       LAPATINIB DITOSYLATE      CHEMBL1201179          2007.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                 LAZERTINIB      CHEMBL4558324          2024.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
        LAZERTINIB MESYLATE      CHEMBL6068478          2024.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
               MOBOCERTINIB      CHEMBL4650319          2021.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
     MOBOCERTINIB SUCCINATE      CHEMBL4802239          2021.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                NECITUMUMAB      CHEMBL1743047          2015.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                  NERATINIB       CHEMBL180022          2017.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
          NERATINIB MALEATE      CHEMBL3989921          2017.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                  OLMUTINIB      CHEMBL3786343          2016.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                OSIMERTINIB      CHEMBL3353410          2015.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       OSIMERTINIB MESYLATE      CHEMBL3545063          2015.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
                PANITUMUMAB      CHEMBL1201827          2006.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
    
    Saved: chembl_egfr_approved_drugs_raw.csv and chembl_egfr_all_molecule_metadata.csv
  20. 파일
    chembl_egfr_all_molecule_metadata.csv
  21. 파일
    chembl_egfr_approved_drugs_raw.csv
  22. 계획
    승인 단계 4인 레코드는 20개였지만, 이에는 같은 활성 성분의 염 형태(예: osimertinib 및 osimertinib mesylate)가 별도 분자로 포함됩니다. 따라서 ChEMBL 분자 계통(molecule hierarchy)의 parent를 조회하여 **활성 성분 기준으로 중복을 제거**하고, 최종 표에 원자료의 ChEMBL ID와 승인 연도를 보존하겠습니다. 1. [✓] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. (P00533 확인) 2. [✓] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. (CHEMBL203 직접 기전 연결 및 분자 승인 단계 확인) 3. [ ] 염 형태를 활성 성분 기준으로 통합하고, 표적-약물 연결·승인 상태를 표로 정리한다.
  23. 코드 python
    python
    import pandas as pd, requests, json, time
    from pathlib import Path
    
    raw = pd.read_csv("chembl_egfr_approved_drugs_raw.csv")
    unique_ids = raw["molecule_chembl_id"].drop_duplicates().tolist()
    details = []
    
    for chembl_id in unique_ids:
        r = requests.get(f"https://www.ebi.ac.uk/chembl/api/data/molecule/{chembl_id}.json", timeout=30)
        r.raise_for_status()
        m = r.json()
        hierarchy = m.get("molecule_hierarchy") or {}
        details.append({
            "listed_chembl_id": chembl_id,
            "listed_name": m.get("pref_name"),
            "parent_chembl_id": hierarchy.get("parent_chembl_id") or chembl_id,
            "active_chembl_id": hierarchy.get("active_chembl_id") or chembl_id,
        })
        time.sleep(0.08)
    
    detail_df = pd.DataFrame(details)
    merged = raw.merge(detail_df, left_on="molecule_chembl_id", right_on="listed_chembl_id")
    canonical = (
        merged.sort_values(["parent_chembl_id", "listed_name"])
        .groupby("parent_chembl_id", as_index=False)
        .agg(
            active_chembl_id=("active_chembl_id", "first"),
            active_ingredient=("listed_name", "first"),
            ChEMBL_records=("listed_name", lambda x: " / ".join(x)),
            first_approval=("first_approval", "min"),
            molecule_type=("molecule_type", "first"),
            withdrawn_flag=("withdrawn_flag", "first"),
            mechanism_of_action=("mechanism_of_action", "first"),
            action_type=("action_type", "first"),
        )
        .sort_values("active_ingredient")
    )
    
    canonical.to_csv("chembl_egfr_approved_drugs_canonical.csv", index=False, encoding="utf-8-sig")
    print("ChEMBL phase-4 records:", len(raw))
    print("Unique active-ingredient parents after hierarchy-based consolidation:", len(canonical))
    print(canonical.to_string(index=False))
    print("\nSaved final canonical table: chembl_egfr_approved_drugs_canonical.csv")
  24. 실행 결과
    실행 결과 보기
    ChEMBL phase-4 records: 20
    Unique active-ingredient parents after hierarchy-based consolidation: 15
    parent_chembl_id active_chembl_id       active_ingredient                        ChEMBL_records  first_approval  molecule_type  withdrawn_flag                              mechanism_of_action action_type
       CHEMBL1173655    CHEMBL1173655      AFATINIB DIMALEATE                    AFATINIB DIMALEATE          2013.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL4297774    CHEMBL4297774             AMIVANTAMAB                           AMIVANTAMAB          2021.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL3545311    CHEMBL3545311              BRIGATINIB                            BRIGATINIB          2017.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL1201577    CHEMBL1201577               CETUXIMAB                             CETUXIMAB          2004.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL2110732    CHEMBL2110732             DACOMITINIB   DACOMITINIB / DACOMITINIB ANHYDROUS          2018.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
           CHEMBL553        CHEMBL553 ERLOTINIB HYDROCHLORIDE               ERLOTINIB HYDROCHLORIDE          2004.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
           CHEMBL939        CHEMBL939               GEFITINIB                             GEFITINIB          2003.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
           CHEMBL554        CHEMBL554    LAPATINIB DITOSYLATE                  LAPATINIB DITOSYLATE          2007.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL4558324    CHEMBL4558324              LAZERTINIB      LAZERTINIB / LAZERTINIB MESYLATE          2024.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL4650319    CHEMBL4650319            MOBOCERTINIB MOBOCERTINIB / MOBOCERTINIB SUCCINATE          2021.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL1743047    CHEMBL1743047             NECITUMUMAB                           NECITUMUMAB          2015.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
        CHEMBL180022     CHEMBL180022               NERATINIB         NERATINIB / NERATINIB MALEATE          2017.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL3786343    CHEMBL3786343               OLMUTINIB                             OLMUTINIB          2016.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL3353410    CHEMBL3353410             OSIMERTINIB    OSIMERTINIB / OSIMERTINIB MESYLATE          2015.0 Small molecule           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
       CHEMBL1201827    CHEMBL1201827             PANITUMUMAB                           PANITUMUMAB          2006.0       Antibody           False Epidermal growth factor receptor erbB1 inhibitor   INHIBITOR
    
    Saved final canonical table: chembl_egfr_approved_drugs_canonical.csv
  25. 파일
    chembl_egfr_approved_drugs_canonical.csv
  26. 계획
    최종 통합 결과로 활성 성분 기준 15개를 확인했습니다. 다만 `max_phase=4`는 ChEMBL의 “최고 임상 단계(승인 포함)” 표지이므로, 해당 국가·적응증에서 현재 유효한 허가를 의미하지 않을 수 있습니다. 이 점을 포함해 결과를 정리하겠습니다. 1. [✓] UniProt에서 인간 EGFR 항목과 기능 주석을 조회한다. (P00533 확인) 2. [✓] ChEMBL에서 EGFR 표적 정보 및 승인(최고 개발 단계 4) 약물 후보를 조회한다. (CHEMBL203, 기전 레코드 90건/고유 분자 76개 중 phase 4 확인) 3. [✓] 염 형태를 활성 성분 기준으로 통합하고, 표적-약물 연결·승인 상태를 표로 정리한다. (20개 ChEMBL 레코드 → 15개 활성 성분/parent로 통합)
## EGFR 단백질 기능: UniProt | 항목 | UniProt 확인 결과 | |---|---| | 단백질 | Epidermal growth factor receptor (EGFR) | | 종 | *Homo sapiens* | | UniProtKB accession | **P00533** (reviewed/Swiss-Prot) | | 단백질 종류 | 세포막 수용체 티로신 키나아제; proto-oncogene c-ErbB-1 | | 효소 분류 | EC **2.7.10.1** | | 촉매 반응 | ATP를 이용하여 단백질의 tyrosine 잔기를 인산화: L-tyrosyl-[protein] + ATP → O-phospho-L-tyrosyl-[protein] + ADP + H⁺ | | 주요 기능 | EGF 계열 리간드(EGF, TGF-α, AREG, EREG, HBEGF 등)가 결합하면 수용체 동종/이종 이합체화와 세포질 잔기의 자가인산화가 유도됩니다. 인산화된 EGFR은 GRB2 등의 어댑터 단백질을 모집하여 세포외 신호를 세포 반응으로 전환합니다. | | 주요 하위 신호 | RAS–RAF–MEK–ERK, PI3K–AKT, PLCγ–PKC, STAT 경로를 활성화하며, NF-κB 신호도 활성화할 수 있습니다. 세포 이동 조절에도 관여합니다. | **출처:** UniProtKB P00533, “Epidermal growth factor receptor” https://www.uniprot.org/uniprotkb/P00533 --- ## ChEMBL에서 확인한 EGFR 표적 승인 약물 ChEMBL의 사람 EGFR 표적은 **CHEMBL203**입니다. 이 표적에 직접 연결된 기전 레코드에서 `action_type = INHIBITOR`이고, 분자 메타데이터의 `max_phase = 4`인 항목을 추출했습니다. 염 형태 중복을 parent/활성 성분 기준으로 통합하여 **15개**로 정리했습니다. | 활성 성분/ChEMBL 표기 | Parent ChEMBL ID | 최초 승인 연도 | 분자 유형 | ChEMBL 기전 | 철회 표지 | |---|---:|---:|---|---|---| | Afatinib dimaleate | CHEMBL1173655 | 2013 | 저분자 | EGFR/erbB1 inhibitor | False | | Amivantamab | CHEMBL4297774 | 2021 | 항체 | EGFR/erbB1 inhibitor | False | | Brigatinib | CHEMBL3545311 | 2017 | 저분자 | EGFR/erbB1 inhibitor | False | | Cetuximab | CHEMBL1201577 | 2004 | 항체 | EGFR/erbB1 inhibitor | False | | Dacomitinib | CHEMBL2110732 | 2018 | 저분자 | EGFR/erbB1 inhibitor | False | | Erlotinib hydrochloride | CHEMBL553 | 2004 | 저분자 | EGFR/erbB1 inhibitor | False | | Gefitinib | CHEMBL939 | 2003 | 저분자 | EGFR/erbB1 inhibitor | False | | Lapatinib ditosylate | CHEMBL554 | 2007 | 저분자 | EGFR/erbB1 inhibitor | False | | Lazertinib | CHEMBL4558324 | 2024 | 저분자 | EGFR/erbB1 inhibitor | False | | Mobocertinib | CHEMBL4650319 | 2021 | 저분자 | EGFR/erbB1 inhibitor | False | | Necitumumab | CHEMBL1743047 | 2015 | 항체 | EGFR/erbB1 inhibitor | False | | Neratinib | CHEMBL180022 | 2017 | 저분자 | EGFR/erbB1 inhibitor | False | | Olmutinib | CHEMBL3786343 | 2016 | 저분자 | EGFR/erbB1 inhibitor | False | | Osimertinib | CHEMBL3353410 | 2015 | 저분자 | EGFR/erbB1 inhibitor | False | | Panitumumab | CHEMBL1201827 | 2006 | 항체 | EGFR/erbB1 inhibitor | False | ### 해석 및 유의점 - ChEMBL 원자료상 phase 4 EGFR 연결 레코드는 20개였으며, **dacomitinib, lazertinib, mobocertinib, neratinib, osimertinib**의 염/무수물 표기를 통합해 15개 활성 성분으로 제시했습니다. - `max_phase = 4`는 ChEMBL에서 승인 단계에 도달했음을 나타내는 분류입니다. 이는 특정 국가에서의 **현재 허가 상태, 적응증, 판매 상태**를 보장하지는 않습니다. - 예를 들어 국가별 규제 상태가 달라질 수 있으므로, 실제 처방·허가 검토에는 해당 규제기관의 최신 라벨을 별도로 확인해야 합니다. - Brigatinib, lapatinib, neratinib 등은 다중 키나아제 표적을 갖는 약물이지만, ChEMBL에 EGFR 억제 기전으로도 연결되어 있어 포함되었습니다. ### 저장 파일 - 활성 성분 기준 통합 표: `chembl_egfr_approved_drugs_canonical.csv` - 원래 phase-4 레코드 20건: `chembl_egfr_approved_drugs_raw.csv` - EGFR 연결 전체 분자 메타데이터: `chembl_egfr_all_molecule_metadata.csv` - CHEMBL203 필터링 기전 원자료: `egfr_chembl_mechanisms.json`
GPT-5.6 Terra · 132초 · 약 $0.16
로그인하면 질문할 수 있습니다
가온은 실수할 수 있습니다 · 공개·비민감 자료만 넣어 주세요